The Korean Journal of Urological Oncology 2009;7(1):6-11.
Published online April 1, 2009.
비근침윤성 방광암의 방광내 약물투여요법
류 현 열, 김 택 상
고신대학교 의과대학 비뇨기과학교실
Update of Intravesical Therapy on Non-Muscle Invasive Bladder Cancer
Hyun Yul Rhew , Taek Sang Kim
Department of Urology, Gospel Hospital, College of Medicine, Kosin University, Busan, Korea
Correspondence:  Hyun Yul Rhew
For non-muscle invasive bladder cancer, intravesical pharmacotherapy after transurethral resection of bladder tumor is widely used for reducing recurrence and progression. All patients with non-muscle invasive bladder cancer, an immediate instillation after transurethral resection of bladder tumor is needed for reduce recurrence. For intermediate and high risk non-muscle invasive bladder cancer patients, adjuvant intravesical chemotherapy or immunotherapy is advised, especially, intravesical BCG instillation is proven to reduce progression. After recurrence or progression, there are many strategies such as second-line intravesical chemotherapy, immunotherapy, device-assisted therapies, or radical cystectomy. We reviewed and summarized the current status of intravesical chemotherapy and immunotherapy. (Korean J Urol Oncol 2009;7:6-11)
Key Words: Bladder cancer, Intravesical chemotherapy, Immunotherapy

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email:
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail:

Copyright © The Korean Urological Oncology Society.

Developed in M2PI